Facebook      Twitter

blank

blank

ONLINE LEARNING CENTER
  Prevention with Positives in HIV Medical Care (11HC06)

Todd Levin, DO, Kelly Rand, MA and Dafne Armstrong, MSW


 
 
 
 

Release Date: June 2009
Expiration Date: EXPIRED May 30, 2011
Activity Code: 11HC06-DE02

CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY.
Content is provided for informational purposes only.

As seen in the June 2009 edition of


ACTIVITY INFORMATION

Sponsor

Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), Center for Continuing & Outreach Education. This activity is supported by an educational grant from NJDHSS Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.

Grantor Acknowledgement

This activity is supported by an educational grant from NJDHSS Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.

Target Audience

This activity is designed for physicians, nurses, social workers and other health care professionals in New Jersey who are involved in the care of persons with HIV/AIDS.

Statement of Need

The CDC recently estimated that 56,300 HIV new infections occur annually in the U.S., significantly more than previous approximations of 40,000 annual new U.S. infections per year. 1 This recognition of the continuing need for HIV prevention efforts follows a decade or more of focusing almost all federally-funded prevention activities on educating youth about abstinence from sexual activity. The CDC, in their landmark report in 2003, Advancing HIV Prevention, recommended that efforts to reduce HIV transmission be focused on behavior change among individuals who are already infected with HIV. Following this release, they funded demonstration projects to identify effective interventions with HIV-positive individuals and groups, to produce “Diffusion of Effective Behavioral Interventions,” or DEBIs, that would provide evidence of their effectiveness and models for replication.

The new case data is indicative of a growing problem in halting the growth of the HIV/AIDS epidemic. As more HIV-positive people achieve stable health through effective treatment, they live longer, and are also active enough to transmit HIV to others through sexual activity and injection drug use. Thus the total number of persons living with HIV/AIDS continues to grow substantially each year. The existing prevention messages, for both HIV-infected and uninfected individuals, have not led to adequate behavior change to reduce new HIV infections, or sexually transmitted infections including syphilis, which has re-emerged as a significant public health concern. New cases of syphilis in the U.S. rose from2.5 per 100,000 in 2002 to 3.8 per 100,000 in 2007.2

1 Centers for Disease Control and Prevention. HIV Prevalence Estimates – United States, 2006. MMWR 2008; 57:39: 1073-6.
2 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2007 Supplement, Syphilis Surveillance Report. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, March 2009. http://www.cdc.gov/std/Syphilis2007/Syphilis2007Short.pdf

Learning Objectives

Upon completion of this learning activity, the reader should be able to:

  • Conduct sexual risk assessment with HIV-positive patients.
  • Test HIV patients for syphilis, chlamydia and gonorrhea at least once every 12 months.
  • Conduct substance use assessment and counseling for all HIV patients at least once every 12 months.

Method of Instruction

Participants should read the learning objectives and review the activity in its entirety. After reviewing the material, complete the self-assessment test which consists of a series of multiple-choice questions. Upon completing this activity as designed and achieving a passing score of 70% or more on the self-assessment test, participants will have access to a printable online credit statement. Estimated time to complete this activity as designed is 1.0 hours.

Accreditation\

EXPIRED- CE is no longer available for this activity. This content is being provided for informational purposes only.

Review

This activity was peer reviewed for relevance, accuracy of content, and balance of presentation by Patricia Kloser, MD, MPH; and Brenda Christian, MEd, PA-C; and pilot tested for relevance and time required for participation by Kinshasa Morton, MD; Bonnie Abedini, RN, MSN; Mary C. Krug, RN, MSN, APN; and Kara Winslow, BSN, RN.

Faculty

Activity Director(s)/CME Academic Advisor(s)

Patricia Kloser, MD, MPH, UMDNJ-New Jersey Medical School

Faculty

  • Todd Levin, DO, is an Infectious Disease Specialist with Garden State Infectious Diseases Associates, PA (GSIDA), in Voorhees, NJ.
  • Kelly Rand, MA, is Clinical Training Coordinator for GSIDA, the Southern New Jersey Local Performance Site of the NY/NJ AIDS Education & Training Center.
  • Dafne Armstrong, MSW is Case Management Supervisor with GSIDA.

Faculty Disclosure Declarations

Todd Levin, DO is on the speakers’ bureau of Gilead Sciences. Debbie Mohammed is on the speakers’ bureaus of BMS and Gilead. Conflicts of interest were resolved by review by Activity Director Patricia Kloser, MD, MPH. The following have no relevant financial relationships to disclose: Authors - Kelly Rand, MA, and Dafne Armstrong, MSW; Activity Director - Patricia Kloser, MD, MPH; Planning committee members - Sindy M. Paul, MD, MPH, FACPM; Linda Berezny, RN, BA; and Kimi Nakata, MSW, MPH (editor); content reviewer Brenda Christian, MEd, PA-C; and field testers: Kinshasa Morton, MD; Bonnie Abedini, MSN, RN; Mary C. Krug, RN, MSN, APN; and Kara Winslow, BSN, RN.

Off-Label Usage Disclosure

This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDHSS-Division of HIV/AIDS Services, UMDNJ, or any manufacturer of pharmaceuticals. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.

Copyright © 2009 UMDNJ-Center for Continuing and Outreach Education. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education. Please direct CME related questions to UMDNJ at 973-972-4267 or email ccoe@ca.rutgers.edu.


 

© Copyright 2014, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy